19 related articles for article (PubMed ID: 31424687)
1. Anti-angiogenesis agents plus chemoradiotherapy for locally advanced nasopharyngeal cancer: a systematic review and meta-analysis.
Sun X; Zhu Y; Lou Y; Lu X; Wang B; Yu D; Guo Y; Xin Y
Eur Arch Otorhinolaryngol; 2024 Apr; ():. PubMed ID: 38625559
[TBL] [Abstract][Full Text] [Related]
2. Effect of cetuximab combined with IMRT and concurrent chemotherapy in treating locally advanced nasopharyngeal carcinoma.
Yang P; Liu J; Yong H; Ma J; Gao X
J BUON; 2021; 26(1):138-144. PubMed ID: 33721444
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab is more effective in nasopharyngeal carcinoma patients with lower maximum radiation dose to the temporal lobe.
Garsa A; Ho JC; Hu C; Chang EL
Chin Clin Oncol; 2019 Oct; 8(S1):S20. PubMed ID: 31280572
[No Abstract] [Full Text] [Related]
4. Maintenance chemotherapy using S-1 following definitive chemoradiotherapy in patients with N3 nasopharyngeal carcinoma.
Zong J; Xu H; Chen B; Guo Q; Xu Y; Chen C; Weng Y; Zheng W; Pan J; Lin S
Radiat Oncol; 2019 Oct; 14(1):182. PubMed ID: 31640719
[TBL] [Abstract][Full Text] [Related]
5. Clinical Variables for Prediction of the Therapeutic Effects of Bevacizumab Monotherapy in Nasopharyngeal Carcinoma Patients With Radiation-Induced Brain Necrosis.
Li Y; Huang X; Jiang J; Hu W; Hu J; Cai J; Rong X; Cheng J; Xu Y; Wu R; Luo J; Tang Y
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):621-629. PubMed ID: 29413276
[TBL] [Abstract][Full Text] [Related]
6. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Chen L; Hu CS; Chen XZ; Hu GQ; Cheng ZB; Sun Y; Li WX; Chen YY; Xie FY; Liang SB; Chen Y; Xu TT; Li B; Long GX; Wang SY; Zheng BM; Guo Y; Sun Y; Mao YP; Tang LL; Chen YM; Liu MZ; Ma J
Lancet Oncol; 2012 Feb; 13(2):163-71. PubMed ID: 22154591
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of chemoradiotherapy combined with bevacizumab in patients with nasopharyngeal carcinoma: A comparative study.
Zhang F; Yuan T; Gao M
J BUON; 2019; 24(3):1252-1258. PubMed ID: 31424687
[TBL] [Abstract][Full Text] [Related]
8. The value of radical radiotherapy in the primary tumor of newly diagnosed oligo-metastatic nasopharyngeal carcinoma patients.
Shuang H; Feng J; Caineng C; Qifeng J; Tin J; Yuanyuan C; Xiaozhong C
Clin Transl Oncol; 2019 Feb; 21(2):213-219. PubMed ID: 29943267
[TBL] [Abstract][Full Text] [Related]
9. Surrogate endpoints for overall survival in combined chemotherapy and radiotherapy trials in nasopharyngeal carcinoma: Meta-analysis of randomised controlled trials.
Chen YP; Sun Y; Chen L; Mao YP; Tang LL; Li WF; Liu X; Zhang WN; Zhou GQ; Guo R; Lin AH; Ma J
Radiother Oncol; 2015 Aug; 116(2):157-66. PubMed ID: 26243677
[TBL] [Abstract][Full Text] [Related]
10.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
